Optimi Health (OPTI) Registration filing summary

Company overview and business model

• Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Vertically integrated with two 10,000 sq. ft. facilities in Princeton, BC, holding Drug Establishment Licence (DEL), Dealer's Licence (DL), and Precursor Licence.

• Products are available in Australia (prescription for TRD and PTSD), Canada (Special Access Program), and for clinical trials in Israel; U.S. market entry pending regulatory changes.

• Focus on scaling pharmaceutical-grade manufacturing, winding down nutraceutical business to concentrate on regulated drug products.

• Competitive strengths include early-mover advantage, scalable operations, regulatory compliance, and strategic partnerships.

Financial performance and metrics

• Revenue for nine months ended June 30, 2025: C$490,330; fiscal year 2024: C$389,850; fiscal year 2023: C$181,087.

• Net loss for nine months ended June 30, 2025: C$2,362,664; fiscal year 2024: C$6,035,859; fiscal year 2023: C$5,194,548.

• Shareholders' equity as of June 30, 2025: C$7,752,490; total assets: C$14,135,865.

• Cash and cash equivalents as of June 30, 2025: C$88,533.

• Company has a history of operating losses and an accumulated deficit of C$25,939,066 as of June 30, 2025.

Use of proceeds and capital allocation

• Net proceeds from the IPO intended for scaling production and distribution, market expansion to Israel and the U.S., sales growth, and general working capital.

• Management has broad discretion over use of funds; additional capital may be needed for U.S. market entry beyond the next 12 months.